S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
New York lawmakers pass $237 billion budget with policies to jump-start housing market
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis

Inozyme Pharma (INZY) Stock Price, News & Analysis

$4.51
-0.07 (-1.53%)
(As of 04/19/2024 ET)
Today's Range
$4.38
$4.63
50-Day Range
$4.51
$7.66
52-Week Range
$2.69
$7.80
Volume
591,071 shs
Average Volume
934,114 shs
Market Capitalization
$278.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00

Inozyme Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
276.9% Upside
$17.00 Price Target
Short Interest
Bearish
6.27% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$52,210 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.46) to ($1.58) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.04 out of 5 stars

Medical Sector

554th out of 909 stocks

Pharmaceutical Preparations Industry

251st out of 425 stocks

INZY stock logo

About Inozyme Pharma Stock (NASDAQ:INZY)

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

INZY Stock Price History

INZY Stock News Headlines

Inozyme Pharma, Inc. (NASDAQ:INZY) Short Interest Update
Incredible Opportunity to Retire FAST!
A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.
Incredible Opportunity to Retire FAST!
A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.
Inozyme Pharma: Q4 Earnings Insights
Inozyme Pharma: Q4 Earnings Insights
INZY May 2024 5.000 put
Bakker Juliet Tammenoms's Net Worth
Inozyme Pharma, Inc. (INZY)
Inozyme Pharma Inc Ordinary Shares INZY
TD Cowen Reaffirms Their Buy Rating on Inozyme Pharma (INZY)
See More Headlines
Receive INZY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inozyme Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/12/2024
Today
4/21/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:INZY
Fax
N/A
Employees
59
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$17.00
High Stock Price Target
$23.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+276.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-71,170,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.27 per share

Miscellaneous

Free Float
54,433,000
Market Cap
$278.58 million
Optionable
Optionable
Beta
1.37
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Douglas A. Treco Ph.D. (Age 66)
    CEO & Chairman
    Comp: $77k
  • Mr. Axel Bolte M.B.A. (Age 52)
    M.Sc., Co-Founder, Senior Advisor & Director
    Comp: $1.03M
  • Mr. Sanjay S. Subramanian M.B.A. (Age 47)
    M.S., Senior VP, CFO & Principal Accounting Officer
    Comp: $726.3k
  • Dr. Demetrios Braddock M.D.
    Ph.D., Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer
  • Dr. Matthew Winton Ph.D. (Age 46)
    Senior VP & COO
  • Dr. Soojin Kim Ph.D.
    Senior VP & Chief Technical Operations Officer
  • Dr. David Thompson M.A.
    M.S., Ph.D., Senior VP, Chief Scientific Officer & Chief Development Officer
  • Mr. Stefan Riley
    Director of Investor Relations
  • Ms. Gayle Gironda
    Senior VP & Chief People Officer
  • Dr. Yves Sabbagh Ph.D.
    Chairman of Scientific Advisory Board & Senior VP

INZY Stock Analysis - Frequently Asked Questions

Should I buy or sell Inozyme Pharma stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inozyme Pharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" INZY shares.
View INZY analyst ratings
or view top-rated stocks.

What is Inozyme Pharma's stock price target for 2024?

4 equities research analysts have issued 12 month price targets for Inozyme Pharma's shares. Their INZY share price targets range from $14.00 to $23.00. On average, they predict the company's stock price to reach $17.00 in the next year. This suggests a possible upside of 276.9% from the stock's current price.
View analysts price targets for INZY
or view top-rated stocks among Wall Street analysts.

How have INZY shares performed in 2024?

Inozyme Pharma's stock was trading at $4.26 at the start of the year. Since then, INZY shares have increased by 5.9% and is now trading at $4.51.
View the best growth stocks for 2024 here
.

Are investors shorting Inozyme Pharma?

Inozyme Pharma saw a increase in short interest in March. As of March 31st, there was short interest totaling 2,580,000 shares, an increase of 8.4% from the March 15th total of 2,380,000 shares. Based on an average daily trading volume, of 611,300 shares, the days-to-cover ratio is presently 4.2 days. Currently, 6.3% of the company's stock are sold short.
View Inozyme Pharma's Short Interest
.

When is Inozyme Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our INZY earnings forecast
.

How were Inozyme Pharma's earnings last quarter?

Inozyme Pharma, Inc. (NASDAQ:INZY) announced its earnings results on Tuesday, March, 12th. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by $0.04.

What other stocks do shareholders of Inozyme Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inozyme Pharma investors own include Procter & Gamble (PG), RTX (RTX), Cisco Systems (CSCO), CSX (CSX), CVS Health (CVS), Home Depot (HD), Resideo Technologies (REZI), Thermo Fisher Scientific (TMO) and Abbott Laboratories (ABT).

When did Inozyme Pharma IPO?

Inozyme Pharma (INZY) raised $75 million in an IPO on Friday, July 24th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

How do I buy shares of Inozyme Pharma?

Shares of INZY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INZY) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners